⚕ GalenOps field
←

716-1298

completed

Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
716 (USA) · Dr. Ito
consented 2013-04-08

AEs
6
Serious
0
Dropout signal
–

Adverse events

moderate assessed

Moderate BLISTER — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-06-08 (study day 62.0); relationship: PROBABLE

moderate assessed

Moderate BLISTER — outcome: RECOVERED/RESOLVED; onset 2013-06-08 (study day 62.0); relationship: PROBABLE

moderate assessed

Moderate ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-04-22 (study day 15.0); relationship: PROBABLE

moderate assessed

Moderate ERYTHEMA — outcome: RECOVERED/RESOLVED; onset 2013-04-22 (study day 15.0); relationship: PROBABLE

moderate assessed

Moderate PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-04-22 (study day 15.0); relationship: PROBABLE

moderate assessed

Moderate PRURITUS — outcome: RECOVERED/RESOLVED; onset 2013-04-22 (study day 15.0); relationship: PROBABLE

Data queries

No data queries.